Intended Use
For In Vitro Diagnostic Use
Summary and Explanation
Vascular endothelial growth factor A (VEGFA) is an important signaling protein involved in both vasculogenesis (the de novo formation of the embryonic circulatory system) and angiogenesis (the growth of blood vessels from pre-existing vasculature). As its name implies, VEGFA activity is restricted mainly to cells of the vascular endothelium, although it has an effect on a limited number of other cell types (e.g., stimulation monocyte/macrophage migration).
VEGFA has been implicated with poor prognosis in breast cancer. The overexpression of VEGFA may be an early step in the process of metastasis, a step involved in the “angiogenic” switch. Although VEGFA has been correlated with poor survival, its exact mechanism of action in the progression of tumors remains unclear. VEGFA is also released in rheumatoid arthritis in response to TNF-alpha, increasing endothelial permeability and swelling and also stimulating angiogenesis (formation of capillaries). Once released, VEGFA may elicit several responses. It may cause a cell to survive, move, or further differentiate.
Presentation
VEGFA antibody is a rabbit monoclonal antibody derived from cell culture supernatant that is concentrated, dialyzed, filter sterilized and diluted in buffer pH 7.5, containing BSA and sodium azide as a preservative.
Synonyms: anti-VEGF, anti VEGF, anti VEGFA, anti-VEGFA, MGC70609, MVCD1, vascular endothelial growth factor A, vascular permeability factor, VEGF, VEGF A, VPF, C1, C 1
